Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity

C. Schellenbacher, B. Huber, M. Skoll, S. Shafti-Keramat, Richard S Roden, R. Kirnbauer

Research output: Contribution to journalArticle

Abstract

The candidate pan-Human Papillomavirus (HPV) vaccine RG1-VLP are HPV16 major capsid protein L1 virus-like-particles (VLP) comprising a type-common epitope of HPV16 minor capsid protein L2 (RG1; aa17-36). Vaccinations have previously demonstrated efficacy against genital high-risk (hr), low-risk (lr) and cutaneous HPV. To compare RG1-VLP to licensed vaccines, rabbits (n = 3) were immunized thrice with 1 µg, 5 µg, 25 µg, or 125 µg of RG1-VLP or a 1/4 dose of Cervarix®. 5 µg of RG1-VLP or 16L1-VLP (Cervarix) induced comparable HPV16 capsid-reactive and neutralizing antibodies titers (62,500/12,500–62,500 or 1000/10,000). 25 µg RG1-VLP induced robust cross-neutralization titers (50–1000) against hrHPV18/31/33/45/52/58/26/70. To mimic reduced immunization schedules in adolescents, mice (n = 10) were immunized twice with RG1-VLP (5 µg) plus 18L1-VLP (5 µg). HPV16 neutralization (titers of 10,000) similar to Cervarix and Gardasil and cross-protection against hrHPV58 vaginal challenge was observed. RG1-VLP vaccination induces hrHPV16 neutralization comparable to similar doses of licensed vaccines, plus cross-neutralization to heterologous hrHPV even when combined with HPV18L1-VLP.

Original languageEnglish (US)
Pages (from-to)3529-3534
Number of pages6
JournalVaccine
Volume37
Issue number27
DOIs
StatePublished - Jun 12 2019

Fingerprint

virus-like particles
Virion
epitopes
Epitopes
Immunity
immunity
neutralization
Papillomaviridae
coat proteins
Capsid Proteins
virus-like particle vaccines
vaccination
Vaccination
Vaccines
vaccines
Cross Protection
Immunization Schedule
capsid
Papillomavirus Vaccines
Capsid

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Schellenbacher, C., Huber, B., Skoll, M., Shafti-Keramat, S., Roden, R. S., & Kirnbauer, R. (2019). Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Vaccine, 37(27), 3529-3534. https://doi.org/10.1016/j.vaccine.2019.05.011

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. / Schellenbacher, C.; Huber, B.; Skoll, M.; Shafti-Keramat, S.; Roden, Richard S; Kirnbauer, R.

In: Vaccine, Vol. 37, No. 27, 12.06.2019, p. 3529-3534.

Research output: Contribution to journalArticle

Schellenbacher, C, Huber, B, Skoll, M, Shafti-Keramat, S, Roden, RS & Kirnbauer, R 2019, 'Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity', Vaccine, vol. 37, no. 27, pp. 3529-3534. https://doi.org/10.1016/j.vaccine.2019.05.011
Schellenbacher C, Huber B, Skoll M, Shafti-Keramat S, Roden RS, Kirnbauer R. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Vaccine. 2019 Jun 12;37(27):3529-3534. https://doi.org/10.1016/j.vaccine.2019.05.011
Schellenbacher, C. ; Huber, B. ; Skoll, M. ; Shafti-Keramat, S. ; Roden, Richard S ; Kirnbauer, R. / Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. In: Vaccine. 2019 ; Vol. 37, No. 27. pp. 3529-3534.
@article{eb4b3691762147af853d262238a7b516,
title = "Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity",
abstract = "The candidate pan-Human Papillomavirus (HPV) vaccine RG1-VLP are HPV16 major capsid protein L1 virus-like-particles (VLP) comprising a type-common epitope of HPV16 minor capsid protein L2 (RG1; aa17-36). Vaccinations have previously demonstrated efficacy against genital high-risk (hr), low-risk (lr) and cutaneous HPV. To compare RG1-VLP to licensed vaccines, rabbits (n = 3) were immunized thrice with 1 µg, 5 µg, 25 µg, or 125 µg of RG1-VLP or a 1/4 dose of Cervarix{\circledR}. 5 µg of RG1-VLP or 16L1-VLP (Cervarix) induced comparable HPV16 capsid-reactive and neutralizing antibodies titers (62,500/12,500–62,500 or 1000/10,000). 25 µg RG1-VLP induced robust cross-neutralization titers (50–1000) against hrHPV18/31/33/45/52/58/26/70. To mimic reduced immunization schedules in adolescents, mice (n = 10) were immunized twice with RG1-VLP (5 µg) plus 18L1-VLP (5 µg). HPV16 neutralization (titers of 10,000) similar to Cervarix and Gardasil and cross-protection against hrHPV58 vaginal challenge was observed. RG1-VLP vaccination induces hrHPV16 neutralization comparable to similar doses of licensed vaccines, plus cross-neutralization to heterologous hrHPV even when combined with HPV18L1-VLP.",
author = "C. Schellenbacher and B. Huber and M. Skoll and S. Shafti-Keramat and Roden, {Richard S} and R. Kirnbauer",
year = "2019",
month = "6",
day = "12",
doi = "10.1016/j.vaccine.2019.05.011",
language = "English (US)",
volume = "37",
pages = "3529--3534",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27",

}

TY - JOUR

T1 - Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity

AU - Schellenbacher, C.

AU - Huber, B.

AU - Skoll, M.

AU - Shafti-Keramat, S.

AU - Roden, Richard S

AU - Kirnbauer, R.

PY - 2019/6/12

Y1 - 2019/6/12

N2 - The candidate pan-Human Papillomavirus (HPV) vaccine RG1-VLP are HPV16 major capsid protein L1 virus-like-particles (VLP) comprising a type-common epitope of HPV16 minor capsid protein L2 (RG1; aa17-36). Vaccinations have previously demonstrated efficacy against genital high-risk (hr), low-risk (lr) and cutaneous HPV. To compare RG1-VLP to licensed vaccines, rabbits (n = 3) were immunized thrice with 1 µg, 5 µg, 25 µg, or 125 µg of RG1-VLP or a 1/4 dose of Cervarix®. 5 µg of RG1-VLP or 16L1-VLP (Cervarix) induced comparable HPV16 capsid-reactive and neutralizing antibodies titers (62,500/12,500–62,500 or 1000/10,000). 25 µg RG1-VLP induced robust cross-neutralization titers (50–1000) against hrHPV18/31/33/45/52/58/26/70. To mimic reduced immunization schedules in adolescents, mice (n = 10) were immunized twice with RG1-VLP (5 µg) plus 18L1-VLP (5 µg). HPV16 neutralization (titers of 10,000) similar to Cervarix and Gardasil and cross-protection against hrHPV58 vaginal challenge was observed. RG1-VLP vaccination induces hrHPV16 neutralization comparable to similar doses of licensed vaccines, plus cross-neutralization to heterologous hrHPV even when combined with HPV18L1-VLP.

AB - The candidate pan-Human Papillomavirus (HPV) vaccine RG1-VLP are HPV16 major capsid protein L1 virus-like-particles (VLP) comprising a type-common epitope of HPV16 minor capsid protein L2 (RG1; aa17-36). Vaccinations have previously demonstrated efficacy against genital high-risk (hr), low-risk (lr) and cutaneous HPV. To compare RG1-VLP to licensed vaccines, rabbits (n = 3) were immunized thrice with 1 µg, 5 µg, 25 µg, or 125 µg of RG1-VLP or a 1/4 dose of Cervarix®. 5 µg of RG1-VLP or 16L1-VLP (Cervarix) induced comparable HPV16 capsid-reactive and neutralizing antibodies titers (62,500/12,500–62,500 or 1000/10,000). 25 µg RG1-VLP induced robust cross-neutralization titers (50–1000) against hrHPV18/31/33/45/52/58/26/70. To mimic reduced immunization schedules in adolescents, mice (n = 10) were immunized twice with RG1-VLP (5 µg) plus 18L1-VLP (5 µg). HPV16 neutralization (titers of 10,000) similar to Cervarix and Gardasil and cross-protection against hrHPV58 vaginal challenge was observed. RG1-VLP vaccination induces hrHPV16 neutralization comparable to similar doses of licensed vaccines, plus cross-neutralization to heterologous hrHPV even when combined with HPV18L1-VLP.

UR - http://www.scopus.com/inward/record.url?scp=85066072529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066072529&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.05.011

DO - 10.1016/j.vaccine.2019.05.011

M3 - Article

C2 - 31147274

AN - SCOPUS:85066072529

VL - 37

SP - 3529

EP - 3534

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27

ER -